| |
| | TAGS GOES HERE --> Markers and Mechanisms of Macrovascular Disease in IDDM (MMMD)</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Markers and Mechanisms of <b>Macrovascular</b> <b>Disease</b> in IDDM (MMMD) </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Principal Investigator: Patricia Cleary, M.S. arkers and Mechanisms of <b>Macrovascular</b> <b>Disease</b> in IDDM is a Program Project sponsored by NIH and the JDF (Juvenile <a href="/topics/Diabetes" title="Diabetes" class=fl>Diabetes</a> Foundation). </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> The overall objectives of the Program Project are to define and elucidate underlying biochemical, metabolic and genetic determinants of <b>macrovascular</b> <b>disease</b> in IDDM patients.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.bsc.gwu.edu /bsc/studies/mmmd.html</font> (137 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://journal.diabetes.org/diabetescare/FullText/Supplements/DiabetesCare/Supplement399/C21.htm">Natural History of Macrovascular Disease and Classic Risk Factors for Atherosclerosis</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Because many of the metabolic risk factors for <b>macrovascular</b> <b>disease</b> improve with the treatment of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a>, particularly with exogenous insulin, there is no reason at present not to pursue optimal management of glycemia with exogenous insulin, if needed. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Presumably, the greater prevalence of <b>macrovascular</b> <b>disease</b> in type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> relates to the prevalence of such abnormalities; however, this inadequately explains the increased incidence and prevalence of <b>macrovascular</b> <b>disease</b> in type 1 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a>, wherein fasting lipids are typically normal and improved only modestly with intensive glycemic control (1). </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Insulin resistance, therefore, could be an explanation as to why patients with impaired glucose tolerance have an increased risk for <b>macrovascular</b> <b>disease</b> in the setting of hyperinsulinemia, whereas that risk increases as insulin secretion fails but insulin resistance increases with a longer duration of type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> (2).</td></tr>
<tr><td></td><td colspan=2><font color=gray>journal.diabetes.org /diabetescare/FullText/Supplements/DiabetesCare/Supplement399/C21.htm</font> (3505 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>BioStratum Incorporated - Lead Drug Candidates</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Hyperglycemia occurring in persons with <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> leads directly to the microvascular (eye, kidney and nerve <b>disease</b>) and <b>macrovascular</b> <b>disease</b> (coronary artery <b>disease</b>, peripheral vascular <b>disease</b> and cerebrovascular <b>disease</b>) associated with <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> One means by which hyperglycemia causes microvascular and <b>macrovascular</b> <b>disease</b> is through the formation of advanced glycation end-products (AGEs). </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Given its ability to inhibit AGE formation and to prevent <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetic</a> renal <b>disease</b> in preclinical models, Pyridorin™ is being developed for the treatment of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetic</a> nephropathy.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.biostratum.com /candidates.html</font> (326 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>Macrovascular disease and systemic sclerosis -- Ho et al. 59 (1): 39 -- Annals of the Rheumatic Diseases</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> the presence of milder <b>disease</b> with ABPI of <1.0, and <0.98. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> <b>macrovascular</b> <b>disease</b> and <b>disease</b> duration or SSc subset (Pearson's </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> In summary, we have shown an increased prevalence of <b>macrovascular</b> <b>disease</b> in SSc.</td></tr>
<tr><td></td><td colspan=2><font color=gray>ard.bmjjournals.com /cgi/content/full/59/1/39</font> (2617 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>Why High Triglycerides Spell Trouble</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> For a man, an HDL cholesterol level of less than 35 mg/dl puts him at high risk for <b>macrovascular</b> <b>disease</b>, a level of 35-45 mg/dl puts him at borderline risk, and a level greater than 45 mg/dl puts him at low risk for <b>macrovascular</b> <b>disease</b>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> For a woman, an HDL cholesterol level of less than 45 mg/dl puts her at high risk for <b>macrovascular</b> <b>disease</b>, a level of 45-55 mg/dl puts her at borderline risk, and a level greater than 55 mg/dl puts her at low risk for <b>macrovascular</b> <b>disease</b>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Inactivity itself is a risk factor for heart <b>disease</b>.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.diabetes-self-mgmt.com /print.cfm?aid=488</font> (2564 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>Clinical Diabetes: Management of Diabetes in the Elderly. @ HighBeam Research</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> The prevalence of risk factors for <b>macrovascular</b> <b>disease</b> (i.e., hypertension, hyperlipidemia, obesity, sedentary lifestyle) are 2-4 times more common in older patients with type 2 diabetes.[12] Moreover, people with type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> are also more likely to have multiple risk factors for coronary heart <b>disease</b> (CHD) than age-matched individuals without <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> While epidemiological data demonstrate that increased glucose levels are associated with increased <b>macrovascular</b> <b>disease</b> events, the impact of especially tight glycemic control on reducing <b>macrovascular</b> events is less certain. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> The prevalence of hypertension in type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetic</a> patients rises from 40% at age 45 to 60% by age 75, a factor that contributes significantly to both macro- and microvascular <b>disease</b> complications.[16,17] Therefore, screening for and aggressive treatment of hypertension are critical components of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> care.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.highbeam.com /library/doc0.asp?DOCID=1G1:53728206&refid=holomed_1</font> (2955 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://secure.pharmacytimes.com/lessons/html/CV_risk_in_diab2.htm">Managing Cardiovascular Risk in Type 2 Diabetes Mellitus</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> <b>Macrovascular</b> complications, such as CVD, are a major cause of morbidity and mortality. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Patients with type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> are often insulin-resistant and present with the insulin resistance syndrome or syndrome X. Insulin resistance syndrome is the clustering of glucose intolerance, central obesity, dyslipidemia, hypertension, and increased prothrombotic and antifibrinolytic factors in an individual. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Insulin resistance and hyperinsulinemia contribute to the pathogenesis of type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> and are risk factors for <b>macrovascular</b> <b>disease</b>.</td></tr>
<tr><td></td><td colspan=2><font color=gray>secure.pharmacytimes.com /lessons/html/CV_risk_in_diab2.htm</font> (4132 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>DARE abstract990495</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> IIT decreased the number of <b>macrovascular</b> events (OR=0.55, 95% CI: 0.35,0.88, P=0.015) but had no significant effect on the number of patients developing <b>macrovascular</b> <b>disease</b> (OR=0.72, 95% CI: 0.44,1.17, P=0.22) or on <b>macrovascular</b> mortality (OR=0.91, 95% CI: 0.31,2.65, P=0.93). </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> The 6 studies were similar in quality; all scored full marks for explicit entry criteria, similarity of baseline characteristics, adequacy of follow-up, and intention-to-treat analyses; the method of randomization was unclear in 3 of the studies. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> IIT decreases the extent of early <b>macrovascular</b> <b>disease</b> in young individuals with type 1 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> but has no effect on the number of patients affected or on <b>macrovascular</b> mortality.</td></tr>
<tr><td></td><td colspan=2><font color=gray>nhscrd.york.ac.uk /online/dare/990495.htm</font> (862 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.childrenwithdiabetes.com/dictionary/m.htm">children with DIABETES - Diabetes Dictionary: M</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> A <b>disease</b> of the large <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a> that sometimes occurs when a person has had <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> for a long time. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> If there is persistent microalbumin over several repeated tests at different times, the risk of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetic</a> nephropathy and <b>macrovascular</b> <b>disease</b> are both higher. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> <b>Disease</b> of the smallest <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a> that sometimes occurs when a person has had <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> for a long time.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.childrenwithdiabetes.com /dictionary/m.htm</font> (1045 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.postgradmed.com/issues/2001/04_01/spanheimer.htm">Postgraduate Medicine: Reducing cardiovascular risk in diabetes</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Although mortality due to cardiovascular <b>disease</b> has continued to decline in nondiabetic populations in the past 25 years, it has remained steady or has increased in the <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetic</a> population. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> There is increasing evidence supporting a role for VLDL triglycerides in <b>macrovascular</b> <b>disease</b> in persons with <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Mortality from coronary heart <b>disease</b> in subjects with type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> and in nondiabetic subjects with and without prior myocardial infarction.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.postgradmed.com /issues/2001/04_01/spanheimer.htm</font> (4081 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.uhseast.com/164776.cfm">Macrovascular diabetes diseases, Eastern Carolina</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> <b>Macrovascular</b> complications of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> are those that affect the large <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a>. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> <a href="/topics/Diabetes" title="Diabetes" class=fl>Diabetes</a> damages the lining of <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a>, causing them to become clogged with plaque, which is made up of cholesterol, white blood cells, calcium, and other substances that collect under the inner lining of an artery. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> When the large <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a> in the legs are affected (peripheral vascular <b>disease</b>), problems with blood circulation to the legs and feet may develop, causing changes in skin color, decreased sensation, and leg cramps.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.uhseast.com /164776.cfm</font> (224 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.emedicine.com/med/topic547.htm">eMedicine - Diabetes Mellitus, Type 2 : Article by William L Isley, MD</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Presumably, patients with IFG are at increased risk for development of <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> mellitus, but their risk for <b>macrovascular</b> <b>disease</b> does not appear to be the same as for patients with IGT (which is about the same as patients with frank type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> mellitus). </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> For women with polycystic ovary <b>disease</b> who ovulate and become pregnant with insulin sensitizer therapy, conversion to insulin is often mandatory as soon as pregnancy is confirmed. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> While postprandial sugars are a better predictor of <b>macrovascular</b> <b>disease</b> risk early in the course of loss of glucose tolerance, whether targeting after-meal glucose excursions has more of an effect on complications risk than more conventional strategies remains to be seen.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.emedicine.com /med/topic547.htm</font> (10373 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><u>Diabetes Self-Management - Why High Triglycerides Spell Trouble</u> <i>(Site not responding. Last check: 2007-10-26)</i></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Here's what is known about the role of triglycerides in <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> and heart <b>disease</b> and, more important, what you can do to keep your triglycerides at a healthy level. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> puts people at greater risk for <b>macrovascular</b> <b>disease</b>, or <b>disease</b> caused by atherosclerosis, the narrowing of the large <a href="/topics/Blood-vessel" title="Blood vessel" class=fl>blood vessels</a> of the body. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> They are also about two to three times more likely to develop cerebrovascular <b>disease</b>, such as strokes and "ministrokes" resulting from a diminished blood supply to the brain.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.diabetes-self-mgmt.com /article.cfm?aid=488</font> (456 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.cmecorner.com/macmcm/aace/aace2004_05.htm">AACE</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> In the prospective Kuopio Ischemic Heart <b>Disease</b> Study, researchers found that moderate physical activity, vigorous physical activity, and fitness level were factors independently associated with metabolic syndrome, with increased physical activity and increased fitness level protecting against the development of this condition (Laaksonen et al. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> It is well known that two thirds of people with <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> die from cardiovascular <b>disease</b> (CVD), and associated <b>macrovascular</b> <b>disease</b> reaches far beyond the coronary arteries. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> According to Dr. Libby, the prevention of diabetes-related <b>macrovascular</b> <b>disease</b> requires a combination of lifestyle and pharmacologic intervention.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.cmecorner.com /macmcm/aace/aace2004_05.htm</font> (2441 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://bmj.bmjjournals.com/cgi/content/full/317/7173/1644">Screening for diabetes: what are we really doing? -- Goyder and Irwig 317 (7173): 1644 -- BMJ</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> For <b>macrovascular</b> complications, there are three distinct ways in which early diagnosis may influence risk. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> The importance of the absolute, rather than relative, risk of <b>macrovascular</b> <b>disease</b> in determining treatment of hypertension </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> Coronary heart <b>disease</b> incidence in NIDDM patients in the Helsinki heart study.</td></tr>
<tr><td></td><td colspan=2><font color=gray>bmj.bmjjournals.com /cgi/content/full/317/7173/1644</font> (1982 words)</td></tr>
</table>
</td>
</tr>
</table><body face="Arial">
<br>
<table cellpadding=0>
<tr>
<td> </td>
<td>
<table >
<tr><td> </td><td colspan=2><a href="http://www.lipidsonline.org/slides/slide01.cfm?q=ukpds&pg=2">Lipids Online Slides: ukpds, diabetes, microvascular complications</a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> There was no statistically significant reduction in the incidence of stroke or peripheral vascular <b>disease</b> in the intensively treated group compared with the group treated with conventional glycemic control. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> In the intensive glucose control arm during the first 10 years, 8.4% of the patients died of either fatal myocardial infarction or sudden death, signifying the importance of coronary heart <b>disease</b> as a primary determinant outcome even in patients with tight glycemic control managed in a clinical trial. </td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> In the UKPDS, a subgroup of patients with type 2 <a href="/topics/Diabetes" title="Diabetes" class=fl>diabetes</a> mellitus was randomized to either 'tight' blood pressure control, in which blood pressure was lowered to a mean of 144/82 mm Hg, or to 'loose' control, in which blood pressure was lowered to a mean of 154/87 mm Hg.</td></tr>
<tr><td></td><td colspan=2><font color=gray>www.lipidsonline.org /slides/slide01.cfm?q=ukpds&pg=2</font> (1227 words)</td></tr>
</table>
</td>
</tr>
</table><script language="JavaScript">
<!--
// This function displays the ad results.
// It must be defined above the script that calls show_ads.js
// to guarantee that it is defined when show_ads.js makes the call-back.
function google_ad_request_done(google_ads) {
// Proceed only if we have ads to display!
if (google_ads.length < 1 )
return;
var s = '';
// For text ads, display each ad in turn.
// In this example, each ad goes in a new row in the table.
if (google_ads[0].type == 'text') {
for(i = 0; i < 1; ++i) {
s = '<body face="Arial"><br><table cellpadding=0><tr><td> </td><td><table ><tr><td> </td><td colspan=2>' +
'<a href="' + google_ads[i].url + '" title="' + google_ads[i].visible_url + '">' + google_ads[i].line1 + '</a> <span style="font-size:10pt">';
if (google_info.feedback_url) {
s += '<a href="' + google_info.feedback_url + '" style="color:#7070F0;text-decoration:none">(Ads by Google)</a>';
} else {
s += '(Ads by Google)';
}
s += '</span></td></tr>' +
'<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td>' + '<a href="' + google_ads[i].url + '" title="' + google_ads[i].visible_url + '" style="text-decoration:none;">' + google_ads[i].line2 + ' ' + google_ads[i].line3 + '</a></td></tr>' +
'<tr><td></td><td colspan=2><font color=gray>' + '<a href="' + google_ads[i].url + '" title="' + google_ads[i].visible_url + '" style="text-decoration:none; color:gray;">' + google_ads[i].visible_url +
'</a></font></td></tr></table></td></tr></table>';
d = document.getElementById('ad' + (i + 1));
d.innerHTML = s;
d.style.display = 'block';
}
s = '';
for(i = 1; i < google_ads.length; i++) {
s += '<div class="r" style="margin-left: 14px"><table cellspacing=0 cellpadding=0><tr>' +
// '<td valign=top><img src="/images/a.gif"/ style="padding-top: 3px; padding-right: 3px"></td>' +
'<td ><a href="' + google_ads[i].url + '" title="' + google_ads[i].visible_url + '">' +
google_ads[i].line1 +
'<div style="text-decoration: none; ">' +
google_ads[i].line2 + ' ' + google_ads[i].line3 + '</div></a>' +
'<font color="gray"><a href="'+ google_ads[i].url + '" title="' + google_ads[i].visible_url + '" style="text-decoration:none; color:gray;">' + google_ads[i].visible_url +
'</a></font>' +
'</td></tr></table></div>'
}
d = document.getElementById('sky1');
d.innerHTML = s;
if(s.length > 0) {
document.getElementById('sky').style.display = 'block';
}
}
/*
<body face="Arial"><br><table cellpadding=0><tr><td> </td><td><table ><tr><td> </td><td colspan=2>
<a href=" ### GOOGLE ADS[i] URL ### "> ### GOOGLE ADS[i] VISIBLE URL ### </a></td></tr>
<tr><td valign=top><img style="margin-top:4px;" src=/images/a.gif></td><td></td><td> ### LINE 2 ### ### LINE 3 ###</td></tr>
<tr><td></td><td colspan=2><font color=gray> ### link ### </font> (sponsored link)</td></tr>
</table></td></tr></table>
*/
/*
// For an image ad, display the image; there will be only one .
if (google_ads[0].type == 'image') {
s += '<tr><td align="center">' +
'<a href="' + google_ads[0].url + '"style="text-decoration: none">' +
'<img src="' + google_ads[0].image_url +
'" height="' + google_ads[0].height +
'" width="' + google_ads[0].width +
'" border="0"></a></td></tr>';
}
// Finish up anything that needs finishing up
s += '</table>';
*/
// document.write(s);
return;
}
-->
</script>
<script language="JavaScript">
<!--
// This script sets the attributes for requesting ads.
google_ad_client = "pub-9457578638026753";
google_max_num_ads = 6;
google_feedback = "on";
google_ad_output = "js";
google_ad_channel = "844964098";
google_kw_type = "broad";
google_kw = "Macrovascular disease";
google_ad_type = "text_image";
google_image_size = "728x90";
google_encoding = "latin1";
-->
</script>
<script language="JavaScript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
<br> <p style="margin-left:30px;font-size:13px;"><b>Try your search on: <a href="http://www.qwika.com/find/Macrovascular disease">Qwika</a> (all wikis)</b></p>
<form action=http://www.factbites.com/search.php><table width="100%" cellspacing=0 cellpadding=0 border=0><tr><td background="/images/f1.gif"><table cellspacing=0 cellpadding=0 border=0 background="/images/b.gif"><tr><td><img src="/images/f2.gif" width=38 height=37 alt=" "/></td><td><table cellspacing=0 cellpadding=0 border=0><tr><td><a href="/"><img src="/images/f3.gif" width=95 height=37 alt="Factbites" border=0 /></a><img src="/images/b.gif" width=15 height=1 alt=" "/></td><td valign=bottom><input type=text size=30 name=kp><img src="/images/b.gif" width=2 height=1 alt=" " /><input type=submit value=" Find » " class=b2></td></tr></table></td></tr><tr><td> </td><td><span class=f>
<a href="http://www.factbites.com/about_us.php">About us</a> |
<a href="http://www.factbites.com/why_use_us.php">Why use us?</a> |
<a href="http://www.factbites.com/reviews.php">Reviews</a> |
<a href="http://www.factbites.com/press.php">Press</a> |
<a href="http://www.factbites.com/contact_us.php">Contact us</a>
<br />Copyright © 2005-2007 www.factbites.com Usage implies agreement with <a href=http://www.factbites.com/terms_and_conditions.php>terms</a>.</span></td></tr></table><img src="/images/b.gif" width=450 height=1 alt=" " /></td></tr></table></form>
<script src="http://www.google-analytics.com/urchin.js" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-317061-4";
urchinTracker();
</script>
</body></html>
| |
